IntroductionThe primary tumor site is unknown prior to treatment in approximately 20% of small bowel (SBNET) and pancreatic (PNET) neuroendocrine tumors despite extensive workup. It can be difficult to discern a PNET from an SBNET on hematoxylin and eosin (H&E) stains, and thus more focused diagnostic tests are required. Immunohistochemistry (IHC) and gene expression profiling are two methods used to identify the tissue of origin from biopsied metastases.
展开▼
